IN8bio’s (INAB) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of IN8bio (NASDAQ:INAB) in a report published on Tuesday,Benzinga reports. HC Wainwright currently has a $8.00 price target on the stock.

IN8bio Trading Up 2.9 %

Shares of IN8bio stock opened at $0.30 on Tuesday. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 0.05. IN8bio has a 12-month low of $0.22 and a 12-month high of $2.48. The company has a market capitalization of $22.08 million, a price-to-earnings ratio of -0.41 and a beta of -0.07. The firm’s 50-day moving average price is $0.30 and its two-hundred day moving average price is $0.63.

IN8bio (NASDAQ:INAB) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). On average, analysts forecast that IN8bio will post -0.56 earnings per share for the current fiscal year.

Institutional Trading of IN8bio

An institutional investor recently raised its position in IN8bio stock. Sigma Planning Corp grew its holdings in shares of IN8bio, Inc. (NASDAQ:INAB) by 42.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 851,280 shares of the company’s stock after acquiring an additional 251,600 shares during the quarter. Sigma Planning Corp owned 1.82% of IN8bio worth $230,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 92.05% of the company’s stock.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.